Business
NurExone Announces Letter of Intent for International Strategic Collaboration with denovoMATRIX Towards Large-Scale Exosome Production
Calgary, Alberta, Canada and Dresden, Germany--(Newsfile Corp. - September 7, 2022) - NurExone...
About this update from Nurexone Biologic Inc
[{"type":"text","content":"NurExone Announces Letter of Intent for International Strategic Collaboration with denovoMATRIX Towards Large-Scale Exosome ProductionCalgary, Alberta, Canada and Dresden, Germany--(Newsfile Corp. - September 7, 2022) - NurExone Biologic Inc. (TSXV: NRX) (FSE: J90) (the \"Company\" or \"NurExone\"), a biopharmaceutical company developing biologically-guided exosome therapy for patients with traumatic spine injuries, is pleased to announce that the Company has entered into a letter of intent (the \"Letter of Intent\") with denovoMATRIX GmbH, a leading German-based developer of innovative technologies which enable cell therapies (\"denovoMATRIX\").Under the Letter of Intent, NurExone will explore collaborations with denovoMATRIX to use its advanced screenMATRIX platform to develop specialized coatings for NurExone's cell carriers for exosome production in order to optimize the manufacturing processes of the non-invasive NurExone's ExoTherapy. The primary aim of the collaboration is to develop a mutually beneficial supply agreement, whereby denovoMATRIX will develop and provide technologies enabling large-scale exosome production.Exosomes are best defined as extracellular vesicles (EVs) that have emerged as promising nanocarriers for drug delivery and targeted therapy, as alternatives to stem cell therapy. EVs are endosome-derived small membrane vesicles, approximately 30 to 150 nm in diameter, and are released into extracellular fluids by cells in all living systems. They are well suited for small functional molecule delivery, and increasing evidence indicates that they have a pivotal role in cell-to-cell communication.NurExone's ExoTherapy uses proprietary exosomes as biologically-guided nanocarriers to deliver specialized therapeutic compounds to target areas. The delivered molecules promote an environment that induces a healing process at the target location. For its first clinical indication of providing recovery of function to traumatic spinal cord injury (SCI) patients, NurExone will use modified siRNA sequences as the delivered therapeutic molecules. ExoTherapy is as promising as a revolutionary, intranasal \"off-the-shelf\" product to treat traumatic Spinal cord injuries as well as damage to the Brain and other Central Nervous System indications. In preclinical animal studies with a fully transected spinal cord, intranasal...